Geoffrey R. Oxnard, MD

Articles by Geoffrey R. Oxnard, MD

42 Tissue and Liquid Biopsy–Based Comprehensive Genomic Profiling Reveal Mechanisms of Therapy Resistance and Rare Targetable Alterations in Breast Cancer

ByEthan Sokol,Smruthy Sivakumar,Dexter X. Jin,Hanna Tukachinsky,Karthikeyan Murugesan,Dean Pavlick,Jeffrey S. Ross, MD,Garrett M. Frampton,Geoffrey R. Oxnard, MD,Priti S. Hegde

April 18th 2022

Use of Erlotinib or Gefitinib as Initial Therapy in Advanced NSCLC

ByGeoffrey R. Oxnard, MD,Vincent A. Miller, MD

April 30th 2010

Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), such as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of patients with non–small-cell lung cancer (NSCLC).

Latest Updated Articles

Use of Erlotinib or Gefitinib as Initial Therapy in Advanced NSCLC
April 30th 2010

Geoffrey R. Oxnard, MD

Articles by Geoffrey R. Oxnard, MD

42 Tissue and Liquid Biopsy–Based Comprehensive Genomic Profiling Reveal Mechanisms of Therapy Resistance and Rare Targetable Alterations in Breast Cancer

Use of Erlotinib or Gefitinib as Initial Therapy in Advanced NSCLC

Latest Updated Articles

Trending on CancerNetwork

EPCORE FL-1 Regimen Shows Value Across R/R Follicular Lymphoma Subgroups

FDA Grants Breakthrough Device Designation to Merlin CP-GEP in Early-Stage Melanoma

Genomic Prostate Score Identifies Biologically Low-Risk Disease

Zanubrutinib/Rituximab Improves PFS in Frontline Mantle Cell Lymphoma

How Will EPCORE FL-1 Subgroup Data Impact R/R Follicular Lymphoma Care?